John Marion Yarborough, Jr., MD

Structural Polymorphism of Cyp2d6 and Cyp2c19 Genes Modifies the Efficacy and Toxicity of Pharmacotherapy for Depressive States

“…This concerns the importance of enzymatic systems that interact with drugs, reducing their concentrations in the body to safe levels. Thus, these systems protect the body from excessive, toxic therapy effects, eliminate drugs from tissues, organs, and systems [5,6,7]. Conversely, without considering patients' pharmacogenetic profiles (typical trial-and-error therapy), the frequency of failures and negative responses can exceed 60% [8].…”